The dataset included patients with moderate CKD; however, patients with severe and end-stage renal disease were excluded from the clinical trials. Outcomes were compared in women with creatinine clearance (CrCl) >60 ml/min, between 60 and 45 ml/min, and <45 ml/min. Among the women, only 14% had a CrCl of <45 ml/min. Two important trends in women undergoing PCI with DES were observed.
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IMPROVING OUTCOMES IN INDIVIDUAL SUBGROUPS
Standard-dose clopidogrel remains the most common negative predictor of late mortality but had no effect on the composite of late major adverse cardiac and cerebrovascular events (11) . In an analysis of the Society of Thoracic Surgeons National Adult Cardiac Database, women undergoing coronary bypass more often had CKD, and CKD was associated with higher operative mortality and post-operative complications.
Female sex, however, was not independently associated with adverse outcomes (12).
CONCLUSIONS
Despite the enormity of data on current DES platforms, there remains a need to examine subgroups and interactions between subgroups to understand the best device for the individual patient. Differences in physiology and pharmacodynamics in women and men necessitate equal representation in clinical trials. Certain high-risk clinical subgroups, such as patients with CKD or diabetes mellitus, also deserve increased attention as both qualitative and quantitative differences may be observed compared with patients without these comorbidities.
